Elinzanetant for Vasomotor Symptoms from Endocrine Therapy for Breast Cancer
Elinzanetant led to a significantly lower frequency of vasomotor symptoms associated with endocrine therapy than placebo. (Funded by Bayer; OASIS-4 ClinicalTrials.gov number, NCT05587296.).
Authors
- Christian Seitz (ORCID: https://orcid.org/0000-0003-2315-9148)
- Gilbert Donders (ORCID: https://orcid.org/0000-0001-9890-6254)
- Claudia Haberland (ORCID: https://orcid.org/0000-0002-5533-1881)
- Lineke Zuurman
- Fátima Cardoso (ORCID: https://orcid.org/0000-0002-6692-2249)
- Nick Panay (ORCID: https://orcid.org/0000-0001-6662-1334)
- Paula Briggs (ORCID: https://orcid.org/0000-0003-0468-9151)
- Donal J. Brennan (ORCID: https://orcid.org/0000-0002-6747-3342)
- Susanne Parke
- Maja Francuski
- Kaisa Laapas
- Michael S. Block (ORCID: https://orcid.org/0000-0003-2263-4277)
- Cecilia Caetano
- Nazanin Haseli-Mashhadi
Institutions
- University College Dublin (IE)
- Champalimaud Foundation (PT)
- University of Liverpool (GB)
- University of Antwerp (BE)
- Mater Misericordiae University Hospital (IE)
- Liverpool Women's Hospital (GB)
- Bayer (Switzerland) (CH)
- Queen Charlotte's and Chelsea Hospital (GB)
- Bayer (Finland) (FI)
- Bayer (United Kingdom) (GB)
- Imperial College London (GB)
- Bayer (Germany) (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-06-02
- DOI
- https://doi.org/10.1056/nejmoa2415566
- Citations
- 22
- Primary Topic
- Estrogen and related hormone effects
- Type
- article
- Field-Weighted Citation Impact
- 39.98
Funders
- Bayer